While a growing number of studies have indicated that Nectin4 may be regarded as a potential target for cancer immunotherapy (18, 19), no study so far has reported the use of Nectin4-targeted CAR-T cells for clinical therapy of malignant solid tumors. This evidence concerns the gene NECTIN4 and cancer.